Pfizer’s Revenue and EPS Growth Rate

Pfizer’s revenue and EPS

Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate of EPS of $0.74 on revenue of ~$13.3 billion.

Pfizer’s Revenue and EPS Growth Rate

The above chart compares Pfizer’s quarterly revenues and EPS since the first quarter of 2017.

Revenue growth rate

Pfizer reported a ~4.4% rise in its second-quarter revenue. Its reported revenue increased to ~$13.5 billion in the quarter compared to $12.9 billion in the second quarter of 2017.

As we discussed earlier, the company’s revenue growth was driven by the strong performance of its Innovative Health segment and partially offset by the lower sales of its products in the Essential Health segment.

By geography, the company’s revenue growth was driven by its strong performance in international markets following the strong sales of both its Innovative Health products and its Essential Health products and offset by lower sales in US markets, where the Essential Health segment reported a decline. We’ll do a detailed analysis of the company’s geographical performance in the next article.

EPS growth rate

Pfizer reported a ~20.9% rise in its EPS in the second quarter. Its adjusted EPS rose to $0.81 in the quarter compared to its adjusted EPS of $0.67 in the second quarter of 2017.

The company’s reported EPS for the second quarter were $0.65, higher than its reported EPS of $0.51 in the second quarter of 2017. Over the last two years, Pfizer’s lowest EPS have been $0.14 in the fourth quarter of 2016, while its highest EPS have been $0.65 in the second quarter of 2018.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 8.7% of its total investments in Pfizer, 8.3% in Merck & Co. (MRK), 4.3% in Johnson & Johnson (JNJ), and 4.6% in Eli Lilly and Company (LLY).